July 18, 2025
Viatris Ophthalmic Drug Fails Phase 3 for Blepharitis; Company Weighs Next Steps
Viatris; ophthalmic drug; Phase 3 study; blepharitis; MR-139; clinical trial failure; drug development; pimecrolimus; pipeline; strategic review
Bayer Extends CEO Bill Anderson’s Contract; Sarepta C-Suite Turmoil
Bill Anderson; Bayer; CEO contract extension; company transformation; restructuring; Sarepta; C-suite changes; pharma industry
Sarepta Reports Third Patient Death in Gene Therapy Studies for Limb-Girdle Muscular Dystrophy
Sarepta Therapeutics; limb-girdle muscular dystrophy; SRP-9004; gene therapy; patient death; acute liver failure; FDA clinical hold; AAV vector; Elevidys; safety concerns
Big Pharma Braces for Potential 200% US Tariffs Amid Uncertainty
pharmaceutical industry; tariffs; Donald Trump; supply chains; onshoring; drug prices; manufacturing; healthcare system
FDA Advisory Panel Rejects GSK’s Blenrep in New Combinations Over Safety, Efficacy Concerns
Blenrep; GSK; FDA Advisory Panel; multiple myeloma; ocular toxicity; safety concerns; DREAMM trials; drug approval; relapsed or refractory multiple myeloma
BioNTech Chief Strategy Officer Departs Amid Oncology Pivot and Major Deals
BioNTech; chief strategy officer; Ryan Richardson; oncology pivot; CureVac acquisition; cancer pipeline; leadership transition
Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal
Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments